In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental ...

Could the stock trend higher still or is it poised for a decline? We think Regeneron is a reasonably good bet at current levels, for a couple of reasons, which we outline below. What Has Driven ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher ... a powerful factor that could impact its near-term stock price. The earnings report, which is expected ...

Regeneron is bearing the brunt of investors of late as Eylea’s sales witness a rapid decline. Earlier, the stock took a hit after an unfavorable ruling in its lawsuit against Amgen in the United ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is trading in the red premarket ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in global sales, which consisted ...

The stock's fall snapped a two-day winning streak.

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product ... down 6.8% from previous close. The stock market overreacts to news, and ...